retatrutide research grade - GLP-1 / GIP / GCGR Tri-Agonist Retatrutide – Power Peptides

When luminal content moves through the gastrointestinal tract, specific macronutrients stimulate the chemosensing machinery, which leads to the modulation of gut hormone release

Researchers at UC Irvine issue a warning that GLP-1RAs may be dangerous for children Source: UC Irvine School of Medicine Irvine, CA, August 28, 2023 A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for childrens health

The medication works by slowing the rate at which food leaves the stomach, creating a feeling of fullness that can last longer after meals

Data come from preclinical studies and phase 2 trials

Semaglutide is a GLP-1 receptor agonist while tirzepatide activates both GIP and GLP-1 receptors, which can lead to larger average weight loss in some trials

The Economic Impact of Levothyroxine Dose Adjustments: the CONTROL HE Study